Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $390.0K | $1.2M | $936.0K | $168.0K | $230.0K | $1.5M | $2.1M |
| Cost of revenue | $0 | $1.4M | −$11.3M | $37.0K | $0 | $0 | $49.0K | $0 |
| Gross profit | $3.5M | −$1.0M | $12.5M | $899.0K | $168.0K | $230.0K | $1.5M | $2.1M |
| Gross margin | 100.0% | -260.8% | 1034.3% | 96.0% | 100.0% | 100.0% | 96.8% | 100.0% |
| R&D | $93.3M | $69.9M | $45.7M | $22.2M | $9.2M | $16.2M | $17.9M | $22.1M |
| Operating income | −$90.8M | −$72.9M | −$62.4M | −$45.1M | −$26.3M | −$31.3M | −$32.0M | −$36.6M |
| EBITDA | −$88.4M | −$71.0M | −$59.4M | −$9.7M | −$25.7M | −$31.1M | −$32.0M | −$36.6M |
| Net income | −$85.2M | −$72.0M | −$53.6M | −$43.0M | −$5.7M | −$30.4M | −$31.1M | −$34.0M |
| Net margin | -2415.1% | -18449.0% | -4444.0% | -4592.8% | -3370.8% | -13230.4% | -2039.5% | -1659.4% |
| EPS (diluted) | -26.45 | -20.69 | -12.97 | -10.39 | -0.84 | -3.65 | -3.71 | -4.18 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-1.58 | $-2.14–$-1.28 | 3 |
| 2027 | $100M | $-0.82 | $-0.82–$-0.82 | 1 |
| 2028 | $5M | $-0.70 | $-0.70–$-0.70 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds LUMO.
No tracked institution reports a position in LUMO as of their last filing.
No one on the platform has traded LUMO yet.
| $335M |
| — |
| LIANYLianBio | $0.12 | -28.13% | $13M | — |
| MGTAMagenta Therapeutics, Inc. | $0.70 | -7.74% | $42M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 20.7× sales vs its 43.7× historical median P/S.
Fair value ≈ $9.17 · price $4.34 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$LUMO Looks like they have finally started enrolling in the phase III “The actual date on which the first participant was enrolled in a clinical study.” Actual start date says 5/20/26! First patient has been enrolled!! https://clinicaltrials.gov/study/NCT06948214
View on StockTwits ↗$LUMO Lumos Pharma Reports Promising Second Quarter 2024 Results and Provides Update on Planned Phase 3 Trial for LUM-201 https://beyondspx.com/article/lumos-pharma-lumo-navigating-the-rare-disease-landscape-with-promising-oral-therapeutics
View on StockTwits ↗$LUMO Lumo and their pointless drug was just another example of private money from early lumo investers needing a vehicle to escape when they grabbed newlink genetics and their $115 million cash pile. 6 bagger off the bottom and left for trash sweepers.
View on StockTwits ↗Two acquisitions closing, to be delisted tonight after the close of extended hours trading - $AY to be acquired by Energy Capital Partners, $22.00 cash - $LUMO to be acquired by Double Point Ventures, $4.25 cash + 1 CVR More Info : https://www.sec.gov/Archives/edgar/data/1601072/000114036124045048/ef20038091_ex99-1.htm https://www.sec.gov/Archives/edgar/data/1126234/000119312524268141/d880311dsc14d9a.htm
View on StockTwits ↗$LUMO Closed my position for a loss. Not happy about it. I do hate this company now.
View on StockTwits ↗$LUMO Anyone have a feel for the trading behavior on this? Seems to be a huge amount of selling built up around $4.32. is it large positions selling out rather than tendering, or is it something more nefarious?
View on StockTwits ↗$LUMO Lumos Pharma (LUMO): Navigating the Rare Disease Landscape with Promising Oral Therapeutics https://beyondspx.com/article/lumos-pharma-lumo-navigating-the-rare-disease-landscape-with-promising-oral-therapeutics
View on StockTwits ↗$TSLA holding till $350. $VSTM and $LUMO next on my list.
View on StockTwits ↗$EBS $CHRS $GRI $LUMO to watch for next 2-3 weeks.
View on StockTwits ↗$EBS $LUMO is free money with $4.25 BO offer and 3 years potential premium on the milestones upto $7.
View on StockTwits ↗$ARDX $LUMO might get counter offer for BO. Keep and eye
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.